News
Important Only
Kymera Therapeutics Announces Positive First-In-Human Results From Phase 1 Healthy Volunteer Clinical Trial Of KT-621
June 2 (Reuters) - Kymera Therapeutics Inc KYMR.O:KYMERA THERAPEUTICS ANNOUNCES POSITIVE FIRST-IN-HUMAN RESULTS FROM PHASE 1 HEALTHY VOLUNTEER CLINICAL TRIAL OF KT-621, A FIRST-IN-CLASS, ORAL STAT6 DEGRADERKYMERA THERAPEUTICS INC - KT-621 WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTSKYMERA THERAPEUT...Reuters
Mon, Jun 2
Nervgen Pharma Reports Positive Topline Data From The Chronic Cohort Of Its Phase 1B/2A Clinical Trial Evaluating Nvg-291 In Spinal Cord Injury
June 2 (Reuters) - NervGen Pharma Corp NGEN.V:NERVGEN PHARMA REPORTS POSITIVE TOPLINE DATA FROM THE CHRONIC COHORT OF ITS PHASE 1B/2A CLINICAL TRIAL EVALUATING NVG-291 IN SPINAL CORD INJURYNERVGEN PHARMA CORP: STUDY MET ITS PRIMARY ENDPOINT BY ACHIEVING STATISTICAL SIGNIFICANCE ON ONE OF ITS TWO PRE...Reuters
Mon, Jun 2
Markel completes acquisition of marine specialist Meco
June 2 - (The Insurer) - Markel Insurance has completed its acquisition of marine-focused managing general agent Meco Group, the company said on Monday.Trading as Meco Specialty, the acquired business will sit within the specialty division of Markel International’s wholesale operation, led by Tom Hi...Reuters
Mon, Jun 2
Regeneron Pharmaceuticals - Interim Results From Ongoing Phase 2 Courage Trial
June 2 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O:INTERIM RESULTS FROM ONGOING PHASE 2 COURAGE TRIAL CONFIRM POTENTIAL TO IMPROVE THE QUALITY OF SEMAGLUTIDE (GLP-1 RECEPTOR AGONIST)-INDUCED WEIGHT LOSS BY PRESERVING LEAN MASSREGENERON PHARMACEUTICALS INC - 35% OF SEMAGLUTIDE-INDUCED WEIGHT LOS...Reuters
Mon, Jun 2
ADVISORY-Alert incorrectly tagged to Ford withdrawn
An alert on Venu Holding's VENU.A founder being featured in a magazine profile was inadvertently tagged to automaker Ford F.N, an unrelated company, and has been withdrawn.There will be no substitute.STORY_NUMBER:nTUABF6VVCSTORY_DATE:02/06/2025STORY_TIME:12:15:03 GMTReuters
Mon, Jun 2
Reviva Announces Positive Full Dataset For 1-Year Phase 3 Recover Open Label Extension Study Evaluating Brilaroxazine In Schizophrenia
June 2 (Reuters) - Reviva Pharmaceuticals Holdings Inc RVPH.O:REVIVA ANNOUNCES POSITIVE FULL DATASET FOR 1-YEAR PHASE 3 RECOVER OPEN LABEL EXTENSION STUDY EVALUATING BRILAROXAZINE IN SCHIZOPHRENIAReuters
Mon, Jun 2
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction In ORIGIN Phase 3 Trial In Adults With IgA Nephropathy
June 2 (Reuters) - Vera Therapeutics Inc VERA.O:VERA THERAPEUTICS ANNOUNCES ATACICEPT ACHIEVED 46% PROTEINURIA REDUCTION IN ORIGIN PHASE 3 TRIAL IN ADULTS WITH IGA NEPHROPATHYVERA THERAPEUTICS INC - TO SUBMIT BLA FOR ATACICEPT TO FDA IN 4Q 2025VERA THERAPEUTICS INC - ATACICEPT SAFETY PROFILE FAVORAB...Reuters
Mon, Jun 2
Richards Packaging Income Fund Announces Acquisition Of DermapenWorld
June 2 (Reuters) - Richards Packaging Income Fund RPI_u.TO:RICHARDS PACKAGING INCOME FUND ANNOUNCES ACQUISITION OF DERMAPENWORLD®RICHARDS PACKAGING INCOME FUND - PURCHASE PRICE OF $40 MILLION FINANCED BY NEW TERM CREDIT FACILITYFurther company coverage: [RPI_u.TO]Reuters
Mon, Jun 2
Hyperfine Announces FDA Clearance Of A New Next-Generation Swoop System Powered By Optive Ai Software
June 2 (Reuters) - Hyperfine Inc HYPR.O:HYPERFINE ANNOUNCES FDA CLEARANCE OF A NEW NEXT-GENERATION SWOOP® SYSTEM POWERED BY OPTIVE AI™ SOFTWARE, DELIVERING A TRANSFORMATIVE LEAP IN IMAGE QUALITYReuters
Mon, Jun 2
Three people reported killed and dozens wounded near aid site in Gaza, medics say
Report is the latest to underscore volatile security situationIsrael says aware of reports of casualties and investigatingGaza Humanitarian Foundation says aid distributed without incidentPrivate, U.S.-backed aid group has been criticised by UNGaza health ministry says 51 killed across enclave in pa...Reuters
Mon, Jun 2
